Clinical Trials List
Protocol NumberM23-324
Active
2025-10-01 - 2030-12-31
Phase I
Recruiting3
-
Trial Applicant
AbbVie
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/01
Investigators and Locations
Co-Principal Investigator
- 鄭富銘 Division of Hematology & Oncology
- 王幸婷 Division of Hematology & Oncology
- 陳珈妤 Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- Wei-Ching Lin Division of Radiology
- Ching Yun Hsieh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 傅蓓安 Division of General Internal Medicine
- Ya-Ping Chen Division of General Internal Medicine
- Sin-Syue Li Division of General Internal Medicine
- 張力常 Division of General Internal Medicine
- Ya-Ting Hsu Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 田豐銘 Division of General Internal Medicine
- MING YAO Division of General Internal Medicine
- 李思慧 Division of Family Medicine
- Shang-Ju Wu Division of General Internal Medicine
- Chien-Chin Lin Division of Others -
- 林明恩 Division of General Internal Medicine
- HSIN-AN HOU Division of General Internal Medicine
- Huai-Hsuan Huang Division of General Internal Medicine
- Wen-Chien Chou Division of Others -
- - - Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
18 participants
-
Global
250 participants
